Impacts of anticancer drug parity laws on mortality rates

Yichen Shen*, Haruko Noguchi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


This study investigates the impacts of anticancer drug parity laws on mortality rates in the United States using a difference-in-differences approach. Using data from 2004 to 2017 Compressed Mortality Files, we show that the anticancer drug parity laws reduce the mortality rate for head/neck malignant cancers but have no impact on malignant cancers of other types. We also rule out an insurance expansion channel that may influence the relationship between anticancer drug parity laws and malignant cancer mortality. Our results are robust to various specifications and falsification tests. Our findings imply that providing equal access to oral anticancer drugs is an effective tool for the prevention of premature mortality.

Original languageEnglish
Article number113714
JournalSocial Science and Medicine
Publication statusPublished - 2021 Mar


  • Anticancer drugs
  • Cancer treatment
  • Difference-in-differences approach
  • Drug insurance
  • Parity law

ASJC Scopus subject areas

  • Health(social science)
  • History and Philosophy of Science


Dive into the research topics of 'Impacts of anticancer drug parity laws on mortality rates'. Together they form a unique fingerprint.

Cite this